Advisory: Alert on TCR2 Therapeutics Wrongly Coded To Broker Research
27/02/2019 24:37
(The alert "TCR2 Therapeutics announces exercise of
over-allotment option" was wrongly coded to Broker Research. For
correctly coded alerts on the news, click urn:newsml:reuters.com:*:nL3N20M06V)
Feb 26 (Reuters) - STORY_NUMBER: FWN20L1GL
STORY_DATE: 26/02/2019
STORY_TIME: 10:30:00
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview